hlx87
mAbexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jan 25, 2026 (NCT07294508)
Timeline
2020s
- Jan 1, 2026
Earliest Phase 2 Sponsor(trial)
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07294508 | Phase 2/Phase 3 (Phase 3) | Jan 25, 2026 | Shanghai Henlius Biotech |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Henlius Biotech | For profit | 1 | 1 | 1 | 2026 |
1 organizations
Page 1 / 1